Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein
The DOI matches its Crossref record.
Abstract
LDL (low-density lipoprotein) is the major carrier of cholesterol in human plasma, and as such is intimately involved in the process of atherosclerosis. The lipoprotein class comprises a number of distinct subfractions, and is commonly divided into large, intermediate and small sized particles. Small, dense LDLs are held to be particularly atherogenic, since these particles are retained preferentially by the artery wall, are readily oxidized and carry an enzyme believed to have an important role in atherosclerosis, i.e. lipoprotein-associated phospholipase A2. Generation of small, dense LDL occurs by intravascular lipoprotein remodelling as a result of disturbances such as Type II diabetes, metabolic syndrome, renal disease and pre-eclampsia. The key predisposing factor is the development of hypertriglyceridaemia, in particular elevation in the plasma concentration of large, triacylglycerol-rich VLDL (very-low-density lipoprotein). This leads to the formation of slowly metabolized LDL particles (5-day residence time), which are subject to exchange processes that remove cholesteryl ester from the particle core and replace it with triacylglycerol. LDL, so altered, is a potential substrate for hepatic lipase; if the activity of the enzyme is high enough, lipolysis will generate smaller, denser particles. Correction of the dyslipidaemia associated with small, dense LDL is possible using fibrates and statins, and this may contribute to the clinical benefits seen with these drugs. Fibrates act to lower plasma triacylglycerol (VLDL) levels, and so correct the underlying metabolic disturbance. Statins remove VLDL particles via receptor-mediated pathways and reduce the residence time (and hence limit the potential for remodelling) of LDL in the circulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small dense LDL are relatively slowly metabolized with a five day residence time, which enhances its atherogenicity [54].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [54]
Citations
Cites
Still being checked.
Cited by
Items 201–227 of 227
Colas, R. A., Lagarde, M., & Calzada, C. (2010) · OpenGrey (Institut de l'Information Scientifique et Technique)
Small Dense Low-density Lipoprotein and Cardiovascular Disease
Suh, S., & Lee, M. (2012) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2012.1.1.1
Miljkovic-Gacic, I. (2004) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Pharmacological treatment of lipid disorders in diabetes
Brown, W. V. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00321.x
Vaidyanathan, V. (2009) · OakTrust (Texas A&M University Libraries)
syndromeof dyslipidaemia in the metabolic
Kolovou, G. D., Anagnostopoulou, K. K., & Cokkinos, D. V. (2006)
Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides
Davidson, M. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00025-4
Ng, T. (2007) · UWA Profiles and Research Repository (UWA)
Tavoosnejad, H., Basati, G., & Keshavarzi, F. (2017) · journal of ilam university of medical sciences · doi:10.29252/sjimu.25.2.55
Farr, S. (2017) · TSpace (University of Toronto)
Rojas, J., Chávez-Castillo, M., Olivar, L. C., & Bermúdez, V. (2013) · Revista Latinoamericana de Hipertensión/Revista Latinoamericana de Hipertensiòn
Taher, J. (2017) · TSpace (University of Toronto) · Cited by 1
Lipoprotein Metabolism and the Treatment of Lipid Disorders
Freeman, M. W. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00042-3
Incidence of Aberrative Lipids in Patients with Coronary Artery Disease
Din, I. U., Ahmad, T., Khan, I., Arafat, S. M. Y., Khan, S. U., & Rauf, M. A. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22166958
Coronary Artery Disease Patients have an Abnormally High Frequency of Aberrant Lipid Profiles
Yaqoob, N., Afridi, M. S., Butt, M. A. R., Khan, M. S., Khalid, F., & Tareen, M. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023171349
Haptoglobin and lipid profile in diabetic nephropathy in Ilorin, Kwara state
Ogunwale, K. A., Bamilosin, S. O., Abdul-Raheem, H. A., Adebayo, D. A., Munirudeen, I., Salaudeen, F. O., Ogunniyi, T. J., & Bunza, J. M. (2023) · KIU Journal of Health Sciences · doi:10.59568/kjhs-2023-3-1-08
VIEIRA, G. I. A., Vieira, S. M. A., da Silva, V. L. R., da Silva, J. D. A., dos Santos, A. S., GALENO, A. A., Pinheiro, S. H. D. M., & de Andrade, I. M. (2024) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.17n.6-278
Sokooti, S., Flores-Guerrero, J. L., Heerspink, H. J. L., Connelly, M. A., Bakker, S. J. L., & Dullaart, R. P. F. (2021) · Figshare · doi:10.6084/m9.figshare.15071330
Sorokin, A. V., Patel, N., Li, H., Hong, C. G., Sampson, M. L., O’Hagan, R., Florida, E. M., Teague, H. L., Playford, M. P., Chen, M. Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22715203
Manousopoulou, A., White, C. H., Hamal, S. A., Nihalani, R., Budoff, M. J., & Garbis, S. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.16.706239
Remnant clearance capacity: a new framework for early type 2 diabetes pathogenesis
Nakajima, K., Murakami, M., & Tanaka, A. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121345 · Cited by 1
Millar, S., Perry, I. J., & Phillips, C. M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.007
The role of PPARalpha and growth hormone in hepatic lipid metaboism and atherosclerosis
Ljungberg, A. (2006) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Metadata
- Authors
- Packard, C. J.
- Affiliations
- Glasgow Royal Infirmary (GB)
- Corresponding author
- Packard, C.J.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2003-10-01
- Volume
- 31
- Issue
- 5
- Pages
- 1066-1069
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2121209370
- Cited by
- 225
- References
- 0
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 3 · 2021: 13 · 2020: 12 · 2019: 6 · 2018: 7 · 2017: 12 · 2016: 9 · 2015: 15 · 2014: 13 · 2013: 10 · 2012: 11
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- small dense LDL, triglyceride-rich lipoproteins, VLDL, hypertriglyceridemia, hepatic lipase, lipolysis, atherosclerosis, lipoprotein-associated phospholipase A2, fibrates, statins, dyslipidemia, cholesterol esters
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Lipoproteins, Lipoproteins, LDL, Models, Biological, Phospholipases A, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.